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The UK ME/CFS Biobank was launched in August 2011 following extensive consultation with pro-
fessionals and patient representatives. The bioresource aims to enhance research on myalgic 
encephalomyelitis/chronic fatigue syndrome (ME/CFS), related to pathophysiology, biomarkers and thera-
peutic approaches. The cohort includes 18–60 year olds, encompassing 284 clinically-confirmed ME/CFS 
cases, 60 neurologist-diagnosed multiple sclerosis (MS) cases, and 135 healthy individuals. The Biobank 
contains blood samples, aliquoted into serum, plasma, peripheral blood mononuclear cells (PBMC), red blood 
cells/granulocyte pellet, whole blood, and RNA (totalling 29,863 aliquots). Extensive dataset (700 clini-
cal and socio-demographic variables/participant) enables comprehensive phenotyping. Potential reuse is 
conditional to ethical approval.
Keywords: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; multiple sclerosis; biobank; biospecimen; 
database
Funding statement: The UK charities Action for M.E., ME Association Ramsay Research Fund, ME Research 
UK, and a private donor funded the initial phase of the UK ME/CFS Biobank, which ran from 2011 to 
2014. The project is currently funded by the National Institute of Allergy and Infectious Diseases of the 
National Institutes of Health (NIH) under Award Number R01AI103629, which was granted in 2013 for 
the longitudinal study of immunological, virological and genetic aspects of ME/CFS; and by the ME Asso-
ciation Ramsay Research Fund under a grant issued in 2016 to open the UK ME/CFS Biobank to external 
researchers, following a Big Give Christmas Challenge crowdfunding campaign. The content of this article 
is solely the responsibility of the authors and does not necessarily represent the official views of any of 
the funders. 
(1) Bioresource Overview
Project description
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 
(ME/CFS) is a disabling illness characterised by incapaci-
tating fatigue and a range of symptoms leading to sub-
stantial reductions in activity levels and quality of life. 
We estimated UK ME/CFS prevalence rates of approxi-
mately 1 in 500, with female-to-male ratio at 3:1 [1]; 
similar statistics have been identified in the US [2] and 
other European countries [3], variations being likely due 
to the clinical criteria used.
Despite significant research advances, ME/CFS aetiol-
ogy and pathophysiology remains elusive. To enhance 
biomedical studies in this area, we conducted a par-
ticipatory study to assess the feasibility of establishing 
a cost-effective disease-specific biobank. Discussions 
with ME/CFS patients and inputs from professionals 
with expertise in human tissue banks, law, ethics and 
ME/CFS guided our UK ME/CFS Biobank proposal. 
Funds from UK ME charities (see Funding state-
ment) enabled the development and establishment of 
the bioresource protocol in August 2011; participant 
recruitment started in March 2012, after ethical clear-
ance (see Ethics Statement). 
This disease-specific biobank was conceptualised and 
is administered by researchers (the CureME team) at the 
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London School of Hygiene & Tropical Medicine (LSHTM); 
while the University College London-Royal Free Hospital 
(UCL-RFH Biobank), a partnering licensed infrastructure 
for biobanking, is responsible for processing, aliquoting 
and storing samples. Release of samples is coordinate 
between both teams. 
The Biobank was concomitantly developed with our 
research proposal on immunological, virological and gene 
expression aspects of ME/CFS, which was later funded 
by the National Institutes of Health (NIH/NIAID – Grant 
Number: 1R01AI103629-01A1). The latter allowed the 
expansion of the initial cohort, which now includes 284 
participants with ME/CFS, 60 with multiple sclerosis and 
135 healthy. A subset was followed-up at 6–12 months.
Samples has been successfully released to the LSHTM 
laboratory teams and results will be published in 2017, 
upon follow-ups completion. The Biobank currently 
accepts external research applications.
Classification (1)
Human.
Species
N/A.
Classification (2)
Biological samples and associated data, clinical data.
Context
Spatial coverage
Description: All data and samples have been collected in 
the United Kingdom, with the majority from East Anglia 
and the Greater London region and a small minority from 
Yorkshire, Sussex, Devon, and Scotland.
Northern boundary: +55.952035/–3.189983.
Southern boundary: +50.377519/–4.144120.
Eastern boundary: +52.474468/+1.749744.
Western boundary: +50.377519/–4.144120.
Temporal coverage
Data and sample collection began on 03/03/2012 and is 
ongoing as of December 2016. The team plans to continue 
recruitment of new participants and longitudinal follow-
up of selected participants until at least 2021, contingent 
on funding.
Temporal coverage for accessibility
There is no planned destruction of the data or samples 
and participant consent covers unrestricted future use of 
both data and samples.
(2) Methods
Steps
The UK ME/CFS Biobank requires a recruitment pro-
cess that encompasses collection of data, clinical meas-
ures, and biosamples. All steps follow specific Standard 
Operating Procedures (SOPs). Most participants are 
recruited through the UK National Health Service (NHS) 
and ME/CFS diagnosis is ascertained for compliance 
with the Canadian Consensus or CDC-1994 criteria 
[4, 5]. Home visits were used for recruitment of severely 
ill patients, who have not been proportionately included 
in previous studies. 
SOPs are followed for: participant identification and 
invitation; determination of eligibility; clinical assess-
ments; blood collection kit preparation and phlebotomy; 
laboratory blood tests; data entry; sample transporta-
tion, receipt, preparation, processing, and storage; peer 
Figure 1: UK ME/CFS Biobank procedures from participant recruitment to storage of samples at the UCL/RFH BioBank.
Lacerda et al: UK ME/CFS Biobank Art. 4 p.  3 of 11 
review of applications to the Biobank; and data and sam-
ple release.
Figure 1 summarises the Biobank recruitment proce-
dures. Figure 2 details sample processing procedures and 
blood derivative outputs.
Researchers are encouraged to contact the CureME 
team at the London School of Hygiene & Tropical 
Medicine for detailed SOPs and protocols related to the 
above activities.
Stabilization/preservation
Whole blood, serum, plasma, granulocyte (and red blood 
cell) post density gradient, and peripheral blood mononu-
clear cell (PBMC) samples are stored in volumes of 200 µl 
to 2ml in 1.0 ml or 2 ml cryotubes. PAXgene tubes (2.5 ml) 
are stored as is, without processing. 
Each aliquot is labelled with a 2D bar code corre-
sponding to a unique 15 digit ISBT 128 (global stand-
ard) identifier. De-identified information relating to the 
subject and samples is securely stored on the University 
College London/Royal Free Hospital (UCL/RFH) BioBank 
database.
Type of long-term preservation
The UK ME/CFS Biobank samples are stored at the UCL/RFH 
BioBank facility, where samples are received, logged, and 
processed (see Figure 2) before frozen for long-term storage. 
Located at the Royal Free London NHS Trust (London UK), 
access to this facility is limited to authorised users only. Staff 
are fully trained in all sample handling procedures.
The repository has a planned capacity of 1 million sam-
ples. The liquid nitrogen (LN2) Cryo-Storage Room is 200 
m2 and the laboratory is 400 m2.
The UCL/RFH BioBank has established full contingency 
plans, including 24-hour monitoring and alarm equipment. 
Back-up LN2 storage tanks and freezers are kept at working 
temperature in case of equipment failure, and a dedicated 
supply of LN2 covers two weeks’ usage. To protect samples 
during electricity loss, the UCL/RFH BioBank is connected 
to the Royal Free Hospital emergency power generator. 
Both institutions – the LSHTM and the UCL/RFH 
BioBank, have be-spoke databases holding the data related 
to participants (the former) and to individual aliquots (the 
latter). Information systems and data are managed and 
daily backed up by their respective IT departments.
Both institutions operate in compliance with the 
Human Tissue Authority (HTA) guidance, which is the UK 
regulator for human tissue and organs.
Storage temperature
PAXgene tubes are kept at –80°C and all other samples are 
stored in vapour phase liquid nitrogen at –180°C.
Shipping temperature from patient/source to 
preservation or research use
Blood samples are collected in BD vacutainers and trans-
ported within Pathopak containers in compliance with UN 
3373 regulations in 2” thick polystyrene boxes at room 
temperature (18–25°C), protected from direct sunlight and 
air conditioning.
Figure 2: UK ME/CFS Biobank processing procedures conducted by the UCL/RFH BioBank (by tube type with blood 
derivative breakdowns).
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Samples are delivered to laboratories for routine testing 
and/or biobanking within six hours of collection by the 
research nurse.
Shipping temperature from storage to research use
–80°C (on dry ice).
Quality assurance measures
Quality control checks on stored samples have assessed 
PBMC viability and yield, cell phenotype and NK cell 
function, and RNA integrity and yield from PAXgene 
tubes (Figures 3 and 4), with reproducibly good 
results. 
Figure 3: PBMC quality control. PBMC are thawed and stained with either a leukocyte antibody cocktail or a T cell 
cocktail. To test NK cell function, PBMC are incubated with cytokines at 5 ng/ml for rhIL–12 (Peprotec) and 50 ng/
ml for IL–18 (R&D Systems) or with MHC Class I-deficient K562 cells for 18 hours, in the presence of anti-CD107a-
FITC (BD Biosciences), then stained with an NK cell function panel. Data are collected using an LSRII flow cytom-
eter using FACS Diva software and analysed using FlowJo software. This figure shows data from samples from 10 
participants recruited at different sites throughout 2012. Cell recovery yielded an average of 3.9×10^6 cells/tube. 
The viability of the recovered cells, assessed by trypan blue exclusion, was excellent in all samples, ranging from 
89.2% to 100%. NK cells in the recovered PBMC were responsive in functional NK cell assays, responding to both 
high-dose cytokines (IL–12 and IL–18) and MHC Class I-deficient (K562) target cells by upregulating expression of 
the high affinity IL–2 receptor (CD25), increasing production of IFN-γ, and undergoing degranulation, measured 
by surface expression of CD107a.
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Source of associated data
At enrolment, all participants complete a Symptoms 
Assessment form to confirm case definition compliance 
and study eligibility. Participants are asked to complete 
additional questionnaires within 48 hours of blood col-
lection, including standard instruments allowing further 
characterisation of cases by clinical phenotype and disease 
severity [7]. Participants complete the questionnaires them-
selves except in very severe cases, when a family member or 
carer may help. Clinical variables have been chosen based 
on the team’s experience with ME/CFS research [1, 8, 9] and 
those routinely collected by the UK Biobank [10]. Clinical 
Figure 4: PAXgene RNA quality control. RNA is extracted using the PAXgene miRNA isolation kit (Preanalytix). RNA 
yield is routinely > 3 µg/sample, with optical density 260/280 nm between 1.8 and 2.2 and all Bioanalyser RNA Integ-
rity (RIN) values greater than 7, as expected for intact, non-degraded samples. To confirm samples were appropriate 
for downstream analysis, quantitative reverse-transcriptase PCR (qRT-PCR) was conducted for five study participants 
for three housekeeping genes: Human large ribosomal protein P0 (HuP0), cyclophilin A, and hypoxanthine-guanine 
phospho-ribosyltransferase (HPRT), using published methodology [6].
Questionnaires Clinical assessments Blood tests
• Symptoms experienced • urinalysis by dipstick (glucose, 
protein, blood, and specific 
gravity)
• full blood count
• Sociodemographic variables • pulse oximetry • blood chemistry and 
creatinine
• Family and individual health 
histories
• blood pressure (seated and 
standing)
• liver function
• Potential risk factors (exposures) • standing height • thyroid function
• Medical Outcomes Survey Short 
Form (SF-36v2) [11]
• weight and bioimpedance • CRP
• General Health Questionnaire 
(GHQ-28) [12, 13]
• waist circumference • ESR
• Epworth sleepiness score [14, 
15]
• hand grip strength test • rheumatoid factor*
• Fatigue scales assessing severity 
[16–18] and disability [17, 19]
• spirometry • tissue transglutaminase 
antibodies*
• Pain and fatigue analogue scale 
[20, 21]
• serum vitamin B12*
• folate*
Table 1: Data available from questionnaires, clinical assessments, and blood tests.
* Available for baseline only.
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assessment data have been collected using standard equip-
ment by a research nurse trained in the study’s clinical 
assessment protocol. Data collected from the questionnaires, 
clinical assessments and blood tests are detailed in Table 1.
The subset of participants being followed-up, are 
assessed with the same procedures for data and sample 
collection, except for some blood tests that are required at 
baseline only (see Table 1). 
A bespoke database securely stores data from question-
naires, clinical assessment, and blood tests results, and 
features algorithms to categorise participants according 
to distinct ME/CFS criteria.
(3) Bioresource description
Object name
Clinical data and blood samples from people with 
ME/CFS, people with MS, and healthy controls.
Bioresource name 
The UK ME/CFS Biobank.
Bioresource location 
The project is led and managed by the CureMe team, 
located within the International Centre for Evidence in 
Disability (ICED), Clinical Research Department, Faculty 
of Infectious and Tropical Diseases, K/490, London 
School of Hygiene & Tropical Medicine (LSHTM), Keppel 
St, London WC1E 7HT, UK. Participant data is securely 
stored at LSHTM in locked files and in a bespoke 
database.
De-identified biological samples are stored at the 
UCL/RFH BioBank facility, 1st Floor, UCL Medical School, 
Royal Free Campus, Rowland Hill St., London NW3 2PF, 
UK. Email: uclrfhbiobank@ucl.ac.uk; website: https://
www.ucl.ac.uk/biobank/uclpphysicalbiobank.
Bioresource contact
mecfsbiobank@LSHTM.ac.uk.
Bioresource URL
http://cureme.LSHTM.ac.uk/the-uk-mecfs-biobank/.
The UK ME/CFS Biobank is one of the Cure-ME pro-
jects, therefore, the bioresouce’s URL is linked to the 
Cure-ME webpage. Researchers are encouraged to to 
seek information through this site and/or contact the 
Cure-ME team.
Bioresource type
A Disease-specific biobank, the UK ME/CFS Biobank 
stores data and blood samples collected from consent-
ing participants with ME/CFS, with MS, and healthy 
controls. The data includes socio-demographic variables, 
clinical measurements, routine blood test results. Blood 
samples are aliquoted for a wide range of research appli-
cations including in virology, immunology, genetic, and 
other types of research. Clinical data is stored at the 
LSHTM and all biological samples are stored at UCL/
RFH BioBank facility. We plan to expand the collection 
to include oral fluid, urine, stool, and other samples, sub-
ject to funding.
Type of sampling 
Participants with ME/CFS and MS are recruited based on 
their disease status, and all must have received a diag-
nosis from a medical professional prior to enrolment. 
Sampling of all participants is largely population-based, 
from primary and secondary health services within the 
study areas. Recruitment of healthy controls is augmented 
through personal referrals and via higher education insti-
tutions, and recruitment of severely-affected participants 
is supplemented through personal referrals and support 
groups to ensure proportional representation in our study 
population, since this segment of the ME/CFS population 
is under-represented in the NHS electronic databases.
Participants with MS and healthy controls serve as 
comparison cohorts and are frequency matched to 
ME/CFS cases by sex, area of residence, and age (within 
five years).
To enable longitudinal studies, a subset of participants 
has been followed up at 6–12 months (including a clinical 
assessment, blood collection, and completion of question-
naires), and additional follow-ups are planned, contingent 
on funding.
Anatomical site 
Venous peripheral blood samples are taken from the arm.
Disease status of patients/source
Participants with “mild” to severe (bed-or housebound) 
ME/CFS; participants with multiple sclerosis; healthy con-
trols who do not have any major morbidity.
Clinical characteristics of patients/source
The team initially assesses case or control eligibility using 
the project’s Symptoms Assessment screening questionnaire.
Inclusion criteria
All participants are aged between 18 and 60 years at the 
time of participation. 
Participants with ME/CFS have been diagnosed by a cli-
nician and are compliant with the Canadian Consensus [4] 
and/or CDC-1994 (“Fukuda”) [5] criteria, as determined 
using responses on the Symptoms Assessment form, 
which feeds a computerised algorithm that maps reported 
symptoms onto ME/CFS study case definitions. 
MS comparators have been diagnosed by a UK NHS neu-
rology consultant [22]. 
Exclusion criteria
Participants must not have: 
•  used drugs in the preceding three months known to 
alter immune function or taken anti-viral medications; 
•  had any vaccinations in the preceding three months; 
•  a history of acute or chronic infectious diseases 
(excluding herpes viruses); 
•  another severe illness such as cancer, coronary heart 
disease, or uncontrolled diabetes; 
•  a severe mood disorder; 
•  been pregnant or breastfeeding in the preceding 12 
months; or
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•  a BMI ≥ 40 (be morbidly obese). 
Vital state of patients/source
Alive.
Clinical diagnosis of patients/source
As described in the Clinical characteristics section 
above, participants with ME/CFS have been diagnosed 
by a clinician and meet the Canadian Consensus [4] 
and/or CDC-1994 (“Fukuda”) [5] criteria. Some participants 
are recruited with a diagnosis of ME/CFS from a medical 
professional but do not fulfil the study’s aforementioned 
criteria after completion of baseline assessments; these 
participants are classified as having “non-ME/CFS chronic 
fatigue”. Compliance with four additional criteria — Oxford 
[23], London [24], Systemic Exertion Intolerance Disease 
[25], and International Consensus Criteria for ME [26] — is 
also assessed, but is not used to determine eligibility. 
MS cases have been diagnosed by a UK NHS neurologist 
consultant [22]. 
Pathology diagnosis
N/A.
Control samples
Healthy controls must not have had any major morbidity 
and must have a BMI < 40. Further details are described in 
the Clinical characteristics section above.
Biospecimen type
Blood, peripheral blood mononuclear cells, DNA, RNA, 
serum, plasma (outlined in Table 2).
Size of the bioresource
As of October 2016, the UK ME/CFS Biobank included 
data and samples from 532 people (including 284 
ME/CFS, 60 MS, 135 healthy control, and 53 non-ME/
CFS chronic fatigue groups), 253 of whom had completed 
a 6–12 month follow-up (Figure 5). Current holdings 
include samples from both time-points; 29,863 aliquots 
are stored as of the end of October, 2016. We collect > 700 
variables for the baseline time-point and > 300 for follow-
ups. Figure 5 details the process for participant invitation 
and enrolment, including total number of participants 
recruited by category and recruitment rates.
The recruitment target for the end of 2016 is 300 peo-
ple with ME/CFS, 75 people with MS, and 150 healthy 
controls. 
There is no planned limit on the number of partici-
pants recruited or samples collected, although we intend 
that samples are released routinely for use in ethically-
approved studies, and then replenished through addi-
tional recruitment. Recruitment is planned to continue 
at least through 2021, including additional time-point 
follow-ups of the current cohort, contingent to funding. 
Release date
Samples and data are available upon successful applica-
tion (see Figure 6).
Access criteria
The Cure-ME team had established the UK ME/CFS 
Biobank, with a governance structure that involves the 
collaboration between two academic institutions – the 
LSHTM (housing the Cure-ME) and the UCL (housing UCL-
RFH BioBank facility). The UK ME/CFS Biobank Steering 
Committee oversees the above team-work, and is also 
involved in assessing research applications, ensuring com-
munity participation in the process.
Academic, non-commercial, and commercial research-
ers are all eligible to apply to use samples and/or 
anonymised data. Applications and review procedures 
are in place (see Bioresource URL). Researchers should 
present a sound scientific rationale for the proposed 
study, have a good research track record, and be sup-
ported by their institution. The following types of studies 
Sample type Stored aliquot/ tube 
volume
Collection tube  
(BD)
Number of  
aliquots
Whole blood 0.5 ml EDTA 3,021
Serum 200 µl Red serum 6,770
Plasma 1 ml EDTA 2,029
Plasma 250 µl Na Hep 5,382
Red Blood Cells (RBCs) 2 ml Na Hep 773
Peripheral Blood Mononuclear 
Cells (PBMCs)
5x106 cells in 1 ml Na Hep 9,106
Peripheral Blood Mononuclear 
Cells (PBMCs)
5x106 cells in 1 ml EDTA 2,198
Blood for RNA 2.5 ml PAXgene 584
Total 29,863
Table 2: UK ME/CFS Biobank sample holdings at the UCL/RFH BioBank (through October 2016).
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Figure 5: Participant invitation and enrolment figures (through October 2016).
will be prioritised: testing or generating new hypotheses 
on pathophysiology of ME/CFS; improving diagnosis and 
phenotyping; and/or, basic science, e.g. pharmacological 
in vitro studies, potentially leading to clinical trials on 
therapeutic approaches.
Applicants are asked to submit a short outline appli-
cation, which will be reviewed by representatives of the 
UK ME/CFS Biobank Steering Committee (i.e. a patient, 
a clinical and a biomedical researcher). Upon approval of 
the outline application, applicants are invited to submit a 
full proposal to be peer-reviewed.
Both the LSHTM and UCL teams work in close con-
tact for ensuring adherence of SOPs, from recruitment 
to sample and/or data release. Requests for usage of 
samples have to follow procedures in compliance with 
current regulations. These includes the local and the 
UCL-RFH BioBank Ethics Review Committee approvals. 
The latter, checks if the proposals are in compliance with 
the UK regulations (Figure 6). Release of data and/or 
samples will occur upon signing of a Materials Transfer 
Agreement and/or Data Transfer Agreement, and 
researchers must not attempt to identify any individuals.
The Biobank was planned to operate on a cost recov-
ery basis to replace released samples, thereby helping 
to ensure the long-term sustainability of the resource. 
Further details are available upon request.
Figure 6 provides further details on the current applica-
tion process, including estimated timeframes.
Additional information and application forms can 
be found on the UK ME/CFS Biobank website: http://
cureme.lshtm.ac.uk/.
(4) Reuse potential
The standardisation and extensiveness of the clinical data 
collected allows classification and stratification of partici-
pants with ME/CFS according to clinical phenotype and 
six disease definitions. Similar data and identical sample 
collection procedures have been followed for all cohorts, 
maximizing the potential of identifying intergroup 
differences.
The team has developed protocols to ensure whole 
blood, plasma, serum, red blood cells, PBMCs, and 
PAXgene samples are suitable for a variety of applica-
tions, including for immunological, virological, genetic, 
and other types of studies. Quality analysis of a sub-
set of stored samples has validated sample collection 
and storage protocols, ensuring that samples are fit for 
purpose. 
Data and samples can be used for high quality, 
high-throughput studies, avoiding the limitations of 
previous studies, which have often been impacted by 
small sample sizes, significant selection bias due to 
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recruitment procedures, and uncertainty about case 
classification accuracy. 
The Biobank’s open access to data and samples from 
our well-defined cohorts will enable high quality research 
with significant savings to users. We are confident that 
this resource will benefit the international community of 
researchers interested in conducting ethical and progressive 
research on ME/CFS, leading to the improved diagnosis and 
treatment of millions of people with ME/CFS worldwide. 
Ethics Statement
The UK ME/CFS Biobank protocol was launched in 2011 
following extensive consultation. Ethical approval granted 
by LSHTM Ethics Committee January 16th, 2012 (Ref.6123) 
and National Research Ethics Service (NRES) London-
Bloomsbury Research Ethics Committee December 22nd, 
2011 (REC ref.11/10/1760, IRAS ID: 77765). LSHTM and 
UCL-RFH Biobank hold Human Tissue Act licences – HTA-
12066 and HTA-11016, respectively. Recruitment of par-
ticipants started March 2012.
The Biobank Steering Committee comprises ME/CFS 
representatives, ME/CFS charity representatives, CureME 
and external researchers. This Committee has overseen the 
Biobank project from onset, and is part of its governance, 
monitoring progress and assessment of external applications.
All participants provide written consent for question-
naire, clinical measurement, and laboratory test data, 
and samples to be made available for ethically-approved 
research (including genetic analyses). Participants are 
posted the consent form and an extensive information 
sheet. The consent form includes an option to withdraw 
from the study at any time. Samples/data will be respect-
fully disposed of under exceptional circumstances, e.g. 
withdrawal of consent with a request of destruction.
No individual research results from the Biobank will 
return to participants or nominated doctors. 
All data/samples are fully de-identified. The key linking 
the anonymised data with identifiers is kept securely by 
the LSHTM project lead.
Constraints
There are no constraints on the ethically-approved usage 
of data or samples, although applications for their use will 
be prioritised according to the UK ME/CFS Biobank’s mis-
sion, three priority areas (outlined in the Access criteria 
section), and available inventory.
Figure 6: Workflow for accessing samples and/or data.
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